Clinical Guidelines

Hypofractionated Locoregional RT in Early Breast Cancer

As reported in The Lancet by Rivera et al, 5-year results of a French phase III trial (UNICANCER HypoG-01) showed noninferiority of hypofractionated locoregional radiotherapy (RT) vs standard 5-week R...

Share

A French phase III trial, UNICANCER HypoG-01, has revealed that hypofractionated locoregional radiotherapy (RT) at 40 Gy over 3 weeks is noninferior to the standard 5-week RT at 50 Gy in reducing the risk of lymphedema in early breast cancer patients. Conducted from September 2016 to March 2020, the study included 1,221 women post-tumor resection and monitored for 4.8 years, finding similar rates of ipsilateral arm lymphedema and adverse effects between the two treatment protocols. The results promise a more efficient treatment option for this patient demographic.

Original Source(s)

Hypofractionated Locoregional RT in Early Breast Cancer

  • by Matthew Stenger

  • March 20, 2026

Related Content

Trauma CT and Unexpected Findings

Investigators evaluate classification of incidental findings on trauma whole-body CT.

Can AI Clarify Lung Screening?

Study assesses comprehension of large language model-generated lung screening summaries

Calcium Score Model Tested in Chest Pain

Investigators compare calcium score–based strategies with universal coronary computed tomography angiography in patients with stable chest pain.